Sight Sciences

Based in California, US, and founded in 2011 by co-founders David Badawi and Paul Badawi, Sight Sciences, Inc. operates as a medical device company that develops eye treatment devices for glaucoma. The company has 169 employees as of June 2021. The company released its IPO in July 2021 and is listed on Nasdaq under the ticker symbol SGHT. The company has 184 employees. The company develops engineered products to target glaucoma and dry eye disease through minimally invasive or non-invasive approaches. The company's OMNI surgical system is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG) which causes irreversible blindness. Sight Sciences provides a TearCare® System which is a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids to relieve dry eye disease. Sight Sciences generated USD 30 million in revenue from March 2020 to March 2021.

1. Series F

   Nov 23, 2020

   Amount

   $23M

   Investors

   Locked

2. Series E

   Mar 17, 2020

   Amount

   $30M

   Investors

   Locked

3. Series C

   May 31, 2018

   Amount

   $9.7M

   Investors

   Locked

4. Series C

   Jul 7, 2017

   Amount

   $10M

   Investors

   Locked

5. Series B

   Mar 15, 2016

   Amount

   $7M

   Investors

   Locked

6. Series A

   Oct 30, 2015

   Amount

   $6.9M

   Investors

   Locked